Abstract. Existence of cancer stem cells (CSCs) is still hypothetical and their practical marker is not available yet in lung cancer. To verify the possible existence of CSCs and to find their markers in lung cancer, we compared the p16/Rb and telomerase status in 83 lung cancer tissues and 15 lung cancer cell lines, since inactivation of p16/Rb pathway is considered to be a prerequisite for normal somatic cells to become immortal cancer cells. We found that 7 of 14 adenocarcinoma, but not squamous cell carcinoma, tissues with high telomerase activity and 3 adenocarcinoma cell lines likely had intact p16/Rb. Such cell lines showed higher colony formation capacity in soft agar compared with inactivated ones with similar growth rate. Moreover, cisplatin-resistant cell line PC9/CDDP with intact p16/Rb, but not PC14/CDDP with its inactivation, increased the colony formation capacity compared with the parent cells. Since CSCs are considered to be resistant to conventional anticancer drugs, they could have been concentrated as long as CSCs existed. We propose that half of immortal lung adenocarcinomas are derived from innately telomerase-positive stem cells, which might be the origin of CSCs, and that high telomerase activity with intact p16/Rb could be a marker of stem cell origin.
Introduction
The new concept describes a cancer stem cell (CSC) as a cell within a tumor that is able to self-renew and to produce the heterogenous lineages of cancer cells that comprise the tumor (1) . Cancer stem cells have been speculated to be the source of many solid tumors including lung cancer (2) , and be resistant to conventional chemo-and radio-therapy. Thus, identification of CSCs and their biomarkers in lung cancer is urgent to improve patient prognosis. Previously, CD133 (PROM1: prominin-1) positive cells (2, 3) , side population cells that extrude Hoechst 33342 dye (4), or aldehyde dehydrogenase positive cells (5) have been demonstrated to be the fractions of putative CSCs in malignant tumors including lung cancer, but they are still not conclusive (6) .
It is widely accepted that CSCs have telomerase activity and are immortal so that they can produce cancer cells indefinitely (7) (8) (9) . But it is not clear yet whether CSCs originate from normal stem cells or from differentiated somatic cells. Since human somatic cells are required to inactivate p16/Rb pathway to overcome cellular senescence and become immortal cancer cells concomitant with activation of telomerase (10, 11) , we hypothesized that immortal cancer cells without inactivation of p16/Rb pathway could not be derived from usual somatic cells, but be originated from innately telomerase-positive cells, i.e., stem cells. We previously found that all examined squamous cell carcinoma and small cell lung cancer (SCLC) tissues with high telomerase activity, meaning immortal cancer cells, had aberrations in RB1 and/or TP53 genes. However, in lung adenocarcinomas with high telomerase activity, neither gene was found in half of the samples (12) . To verify this hypothesis, we examined p16 status in 83 lung cancer tissues and 15 lung cancer cell lines, and compared the relationship between the p16/Rb pathway status and the telomerase activity levels or colony formation capacities.
Materials and methods
Tumor samples. A total of 83 surgically resected primary lung cancer tissues, including 42 adenocarcinomas, 30 squamous cell carcinomas, 4 adenosquamous cell carcinomas, and 7 SCLCs, were obtained from chemotherapy-naïve patients, as well as the corresponding adjacent non-cancer lung tissue samples as controls. All tissues had been provided by the Department of Pathology and Department of Molecular and Internal Medicine, Hiroshima University between 1991-1996. Their pathological stages had been assessed according to the International Staging System (13) and telomerase activity, RB1 loss of heterozygosity (LOH), TP53 LOH, and chromo-some 1p deletion mapping were previously reported (12, (14) (15) (16) . Written informed consent was obtained from all patients before surgery, and this study was approved by our Institutional Ethics Committee.
Cell lines. The SCLC cell line PC-6 and its SN-38-and CPT-11-resistant variants (SN2-5 and DQ2-2), a lung squamous cell carcinoma cell line LC-S, and lung adenocarcinoma cell lines PC-9 and PC-14 and their CDDP-resistant variants (PC-9/CDDP and PC-14/CDDP, respectively) as well as A549 were prepared and examined for CDDP sensitivity as previously described (17) . The remaining 6 lung adenocarcinoma cell lines, RERF-LC-MS, VMRC-LCD, PC-3, RERF-LC-Ad1, RERF-LC-Ad2, and RERF-LC-KJ, and control fibroblast strain TIG-1 were obtained from the Health Science Research Resources Bank (Osaka, Japan).
Colony formation assay with soft agar. Anchorage-dependency of 11 lung adenocarcinoma cell lines was evaluated by conventional colony formation assay with soft agar in triplicate, as previous reported (18) . Briefly, 5x10 3 cells were cultured in 0.4% SeaPlaque GTG agarose (Bioproducts), and after 14 and 21 days of culture at 37˚C with 5% CO 2 , colony number was counted under microscopy for slow-growing cells (colonies containing >5 cells were counted) and macroscopically with crystal violet staining for rapid growing cells (colonies macroscopically visible were counted).
Preparation of DNA and RNA. For tissue samples, genomic DNA had been prepared previously (15) . For cell lines genomic DNA and total RNA were extracted from the frozen cell pellets using QIAamp™ DNA Mini kit (Qiagen Inc., Valencia, CA) and Qiagen RNeasy™ mini kit (Qiagen), respectively, according to the manufacturer's protocols.
Real-time RT-PCR for evaluation of mRNA levels. For cell lines, 2 μg of total RNA was reverse-transcribed using HighCapacity cDNA Archive™ Kit (Applied Biosystems, Foster City, CA, USA). An aliquot of the cDNA (equivalent to 10 ng total RNA) was subjected to each real-time RT-PCR using Universal Probe Library (UPL, Roche Diagnostics, Tokyo, Japan) for CDKN2A (p16), PROM1, BMI1, and ABCG2, TaqMan Gene Expression Assays for RB1 (Hs00153108_m1 targeting exons 24-25, Applied Biosystems), and PreDeveloped TaqMan Assay Reagents (Applied Biosystems) for ACTB as an internal control. Each reaction was carried out in duplicate or triplicate using ABI PRISM™ 7900HT Sequence Detection System (Applied Biosystems) and relative gene expression levels calculated as ratio to ACTB expression level were standardized using a pooled cDNA derived from 17 various cancer cell lines Real-time PCR for quantitation of DNA amounts. Homozygous deletion of CDKN2A was determined by TaqMan™ quantitative real-time PCR system with TagMan Universal PCR master mix and the ABI PRISM™ 7900HT Sequence Detection System (Applied Biosystems) using TFRC as control gene amount (12) . Using a 384-well reaction plate (Applied Biosystems), 20 ng of genomic DNA and 2 sets of primers (final concentration 200 nM each for CDKN2A and 300 and 900 nM for TFRC forward and reverse primers, respectively) and fluorescent-probes (final concentration 100 nM for FAMlabeled CDKN2A and 200 nM for VIC-labeled TFRC) were mixed in a 10-μl reaction mixture. The primer and probe set for TFRC was previously reported (12) and that for CDKN2A is as follows: CDKN2A-F: 5'-AGCTTCCTTTCCGTCA TGC-3'. CDKN2A-R: 5'-TCATGACCTGCCAGAGAGAA-3'. CDKN2A-probe: UPL no. 21 (Roche). Threshold cycle (Ct) for each gene was determined using thermocycler software and the average of 3 independent Cts was calculated. Standard DNA was prepared by mixing genomic DNAs derived from two samples, non-cancer cells with intact CDKN2A and a cancer cell line with homologous deletion, at 10:0 (STD-100%), 8:2 (-80%), 6:4 (-60%), 4:6 (-40%), 2:8 (-20%), and 0:10 (0%).
Fragment analysis for detection of LOH. LOH of CDKN2A was evaluated by fragment length analysis using microsatellite marker D9S1748. The FAM-labeled forward primer (5'-CACCTCAGAAGTCAGTGAGT-3') and a non-labeled reverse primer (5'-GTGCTTGAAATACACCTTTCC-3') were mixed with 20 ng of genomic DNA and subjected to PCR followed by fragment analysis using ABI PRISM 310 Genetic Analyzer and GeneScan™ software as previously described (12) . The adjacent non-cancer lung tissue samples were used as controls of peak height ratio of the corresponding repeat numbers.
Fragment analysis for quantitative methylation-specific PCR (qMSP). MSP was carried out to evaluate the CDKN2A (p16) CpG island methylation status according to a previous report (19) with quantitative modification. The bisulfite-treated genomic DNA was first amplified with outside non-fluorescent primers (35 cycles, annealing at 60˚C) and then nested PCR was carried out using FAM-labeled methylated or HEXlabeled unmethylated allele-specific primers with annealing temperature at 65˚C. Then, 0.5 μl each of methylated (FAM labeled) and unmethylated (HEX labeled) PCR products were mixed and subjected to ABI PRISM 310 Genetic Analyzer (Applied Biosystems). The methylation ratio was calculated as (area of FAM peak)/(areas of FAM peak + HEX peak).
Direct sequence analysis for RB1 cDNA. cDNAs derived from the 15 lung cancer cell lines were subjected to PCR using 2 sets of primers amplifying exons 10-26 that cover almost all naturally occurring RB1 mutations. The PCR condition was 95˚C for 15 min followed by 40 cycles of 95˚C for 30 sec, 58˚C for 1 min, and 72˚C for 90 sec. Sequence analyses were carried out using Big Dye Terminator v1.1 Cycle Sequencing INTERNATIONAL JOURNAL OF ONCOLOGY 36: 1217-1227, 2010 Table I . The genetic aberrations in 83 primary lung cancers. 
Previously analyzed for Tel (telomerase activity level), TP53 (LOH in TP53), RB1 (LOH in RB1), 1p34 (deletion within 1p34 to pter) (12, (14) (15) (16) . qMSP, (methylated allele peak)/(methylated + unmethylated allele peaks) area ratio >0.25 was considered as methylated; HD, homologous deletion; NI, not informative.
Telomerase activity and other genetic aberrations. Among the genetic aberrations in the tissue samples summarized in Table I , we previously evaluated and reported the telomerase activity level by TRAP assay (14) , 1p34 LOH by deletion mapping using 12 polymorphic markers (16) , and LOH of TP53 and RB1 genes using 5 and 4 polymorphic markers, respectively (12, 15) .
Statistical analysis. All statistical tests were performed using StatView version 5.0 software (SAS Institute Inc., Cary, NC, USA), and the Student's t-test, ¯2, or Fisher's exact test was used to determined the P-value. Differences of P<0.05 were considered statistically significant.
Results
Telomerase activity levels and LOH of TP53, RB1, and 1p34 locus in the lung cancer tissues have been evaluated previously (12, (14) (15) (16) and summarized in Table I with the present data. p16 inactivation. Persistent type inactivation of p16 was evaluated by the existence of CDKN2A homozygous deletion, LOH, and/or promoter methylation in 83 lung cancer tissues, and by CDKN2A homozygous deletion or complete promoter methylation in 15 lung cancer cell lines.
Homozygous deletion, [threshold cycles (Ct) of TFRC]-(Ct of CDKN2A) was smaller in a sample than that of 60% (for tissue samples) or 20% (for cell lines) standards in real-time PCR considering the existence of contaminated non-cancer cells in tissue samples, was found in 3 adenocarcinoma, 6 squamous cell carcinoma, 2 adenosquamous cell carcinoma, and 1 SCLC tissues and 6 adenocarcinoma cell lines (Fig. 1) and 1 squamous cell carcinoma cell line, LC-S. LOH, i.e., the calculated peak height ratio of the 2 alleles was <70% or >150% of that in normal counterpart in fragment analysis, was found in 10 tissue samples (Fig. 2) . Cell lines could not be analyzed for LOH due to the lack of normal counterpart.
For evaluating CDKN2A promoter methylation, we considered it methylated when the methylated allele ratio, (methylated allele peak area)/(methylated and unmethylated allele peak areas), was >25%, and complete methylation when the ratio was >80% (Fig. 3) . The CDKN2A promoter methylation was detected in 61.9% (26/42) of adenocarcinoma, but none of squamous cell carcinomas. For lung cancer cell lines, RERF-LC-MS was completely methylated among the 8 cell lines that retained CDKN2A gene. Thus, p16 inactivation by deletion or promoter methylation is summarized in Tables  II and III , and such inactivation in adenocarcinoma tissues revealed to be highly associated with low/nil telomerase activity (P=0.0001).
Rb inactivation. Inactivation of Rb was evaluated by the existence of RB1 LOH (analyzed for 1 RFLP and 3 microsatellite loci) in 83 lung cancer tissues and by the existence of genetic aberrations in RB1 cDNA (sequence analysis of exons [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , that cover the mutation hot-spot region) or absence of RB1 mRNA detection (real-time RT-PCR) in the 15 lung cancer cell lines.
For the 83 lung cancer tissue samples, we previously analyzed and reported that RB1 LOH was found in 26 (34.2%) of 76 non-small cell lung cancer (NSCLC) and 5 (71.4%) of 7 SCLC tissues (12, 15) . Among the 15 lung cancer cell lines examined, RB1 expression could not be detected in 1 adenocarcinoma cell line, RERF-LC-KJ (Fig. 4A) . Also by sequence analysis of RB1 cDNA, only this cell line was revealed to have an aberration, an inframe deletion of 174 nucleotides by splicing out the entire exons 24 and 25. Inactivation of p16/Rb pathway. Combining above, inactivation of p16/Rb pathway, i.e., deletion/methylation of p16 and/or LOH of RB1, among the 83 lung cancer tissues was found in all 28 (100%) with low/nil telomerase activity but in only 7 of 14 (50%) with high telomerase activity (P=0.0001) in adenocarcinomas, whereas this relationship was the opposite in the remaining histology tumors (P=0.0309) ( Table II) . The p16 inactivation was inversely correlated with RB1 LOH in adenocarcinoma tissues (P=0.0488).
Among the 15 lung cancer cell lines, the Rb inactivated cell line RERF-LC-KJ showed intact p16 as expected. Among the 11 adenocarcinoma cell lines, the p16/Rb pathway was considered to be intact in PC-9, its CDDP resistant variant PC-9/CDDP, and RERF-LC-Ad2 (p16/Rb pathway intact group) and inactivated in the remaining 8 cell lines (inactivated group). Then, cellular growth rate and colony formation capacity were carried out between these 2 groups.
Expression of cancer stem cell markers. As known cancer stem cell markers, we evaluated mRNA expression levels of PROM1 (CD133), BMI1, and ABCG2 by real-time RT-PCR in the 15 lung cancer cell lines. While the expression levels of BMI1 and ABCG2 genes were comparable among the all cell lines except for ABCG2 in the drug resistant SCLC clones, PROM1 was highly expressed in RERF-LC-Ad2, in which the p16/Rb pathway was considered to be intact (Fig. 4B) .
Growth rate of adenocarcinoma cell lines. We found that the 11 adenocarcinoma cell lines can be divided into 2 groups according to their growth rates: >20 times multiplied at day 5 (rapid growth group, Fig. 5A ) and less than that (slow growth group, Fig. 5B ). The p16/Rb-intact cell lines PC-9 and PC-9/ Figure 2 . Detection of LOH of p16 by fragment analysis in representative samples. LOH, in cancer tissues was defined when the peak height ratio of heterozygous bands was <0.7 or >1.5 of expected ratio calculated from the normal counterpart. * Deleted allele demonstrating low peak possibly derived from contaminated non-cancer cells. CDDP in the former group and RERF-LC-Ad2 in the latter group did not show accelerated growth compared to the inactivated ones in each group.
Colony formation assay with soft agar. While the colonies in the rapid growth group were evaluated macroscopically after crystal violet staining (Figs. 5C and 6) , those in the slow Table II . Inactivation of p16/Rb in 83 lung cancer tissues. 
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a Previously analyzed for telomerase activity level and RB1 LOH (12,14-16).
- Table III . Inactivation of p16/Rb in lung cancer cell lines.
RT-PCR +, not detectable by real-time RT-PCR; qMSP, methylation ratio >0.8 was considered as completely inactivated; HD, homologous deletion; NI, not informative. growth group were evaluated microscopically before staining, since they were small and macroscopically invisible in general even after 3 weeks (Fig. 5D) . The p16/Rb intact cell lines, PC-9 and PC-9/CDDP in the rapid growth group and RERF-LC-Ad2 in the slow growth group, showed significantly higher colony formation capacity than the p16/Rb inactivated cell lines in each group (P<0.01-P<0.0001). Moreover, CDDPresistant clone with intact p16/Rb (PC-9/CDDP), but not that with p16/Rb inactivation (PC-14/CDDP), showed significantly higher colony formation capacity than the parent clone (P<0.001, Figs. 5C and 6).
Discussion
Most malignant tumors must have a mechanism for bypassing senescence to acquire the unlimited proliferative capacity that is required for advanced cancers. Human somatic cells are considered to have two stages of checkpoint before acquiring immortality (two-stage model for cellular senescence): mortality stage 1 (M1) that can be overcome by inactivation of p16/Rb and p53 pathways and mortality stage 2 (M2), that requires activation of telomerase to be overcome (11, 20) . In fact, we previously found that all examined lung squamous cell carcinoma and SCLC tissues with high telomerase activity had aberrations in RB1 and/or TP53 genes. However, in lung adenocarcinomas with high telomerase activity, neither gene was found in half of them (12) . We also showed that cancer tissues with high telomerase activity consisted of predominantly telomerase positive cells, i.e., immortal cancer cells, while those with low telomerase activity consisted of predominantly telomerase negative cells (21) , and lung cancer cell lines always showed high telomerase activity (14) . In addition, we confirmed full-length type TERT mRNA expression in all 15 lung cancer cell lines used in the present study by real-time RT-PCR, which had been confirmed to correlate with telomerase activity (22) . Since we previously found that lung cancers which might have originated from telomerase positive bronchial epithelia always showed high telomerase activity (23) , lung cancers with high telomerase activity, consist of predominantly immortal cancer cells, and immortal lung cancer cell lines might have been derived from either of the two pathways: developed from telomerase positive normal cells, i.e., stem cells, or from telomerase negative somatic cells through multiple clonal selections acquiring genetic aberrations including TP53, CDKN2A, and/or RB1 inactivation and telomerase activation.
To confirm this hypothesis, we examined incidence of persistent type p16 inactivation (deletion and/or methylation of CDKN2A) in the tissue samples as well as p16/Rb status and colony formation capacity in cell lines in the present study. It has been reported that the inactivation of p16 occurs most prominently through promoter methylation or homozygous deletion and less often through mutation in lung cancers (24) . As we speculated, persistent inactivation of p16/Rb pathway, deletion of CDKN2A or RB1 or methylation of CDKN2A promoter, was found in all adenocarcinoma tissues with low/nil telomerase activity, while neither was found in half of adenocarcinomas with high telomerase activity (P=0.0001). For other genetic aberrations, we previously reported that the RB1 LOH was associated with TP53 and 1p34 LOH but not with EGFR aberrations (12) . In the present study, 5 of 7 p16/Rb intact adenocarcinomas with high telomerase activity also lacked the TP53 LOH and 4 of them lacked both TP53 and 1p34 LOH ( Table I ), indicating that these cases have escaped the M1 stage without persistent inactivation of p16/Rb pathway, p53 pathway, and the unknown pathway involving 1p34 locus. The importance of the p16/Rb and p53 pathways in lung epithelial cells is known by the high incidence of their defects in any histological type of lung cancer (25) , and the adenocarcinomas without their persistent inactivation may have come without these checkpoints.
It has been indicated that only a small proportion of the tumor cells are able to form colonies in an in vitro colonogenic assay (26) , and we found that adenocarcinoma cell lines without persistent inactivation of p16/Rb pathway had higher colony formation capacity in soft agar. Moreover, CDDPresistant clone with intact p16/Rb (PC-9/CDDP), but not one with inactivation (PC-14/CDDP), showed higher colony formation capacity than the parent clones. Although the evidence is not sufficient yet, this could be explained that the former contained CSCs and enriched them in the CDDPresistant clone, because CSCs are considered to be resistant to conventional chemotherapeutic drugs (2), while the latter did not contain CSCs originally and could not enrich the resistant clone. We also examined the expression levels of the known cancer stem cell markers, PROM1 (2), BMI1 (7), and ABCG2 (27) in 15 lung cancer cell lines, and found that the p16/Rb intact cell line RERF-LC-Ad2 showed markedly high expression of PROM1, supporting our hypothesis that the p16/Rb intact immortal cancer cells may have derived from stem cells, and none of the presently available CSC markers is sufficient for all types of lung cancer.
Taken together, the present data indicate that 7 (50%) of 14 lung adenocarcinoma tissues with high telomerase activity (indicating they are predominantly consist of immortal cancer cells) and 3 of 11 (or 2 of 9 parent) lung adenocarcinoma cell lines, PC-9, PC-9/CDDP, and RERF-LC-Ad2, may have developed from M1 escaped cells, i.e., innately telomerasepositive stem cells, which are considered to be the origin of CSCs. Some of SCLC may have derived from such cells, because 1 of 6 SCLC tissues with high telomerase activity and 1 original (PC-6) as well as its 2 drug-resistant cell clones showed intact p16/Rb pathway (Fig. 7) . However, for squamous cell carcinoma, no tissue with high telomerase activity nor the cell line examined showed intact p16/Rb pathway, indicating that it is always required to overcome the M1 stage to become immortal squamous cell carcinoma cells and that the telomerase-negative somatic cells may be of such origin. This speculation may be partly supported by the facts that squamous cell carcinoma often demonstrates evidence of multistep carcinogenesis, i.e., hyperplasia, metaplasia, dysplasia, carcinoma in situ, and invasive cancer, while adenocarcinoma and SCLC often lack such precancerous lesions indicating de novo carcinogenesis. Thus, we propose that there are two distinct pathways in lung carcinogenesis: one from primarily telomerase-positive cells, i.e., stem cells, independent of p16/Rb checkpoint mechanism in M1 stage, while the other from telomerase-negative somatic cells overcoming the M1 stage by inactivation of the p16/Rb and p53 pathways.
In conclusion, our study showed new important insights into lung CSCs. In particular, high telomerase expression without p16/Rb aberration possibly is a marker of cancer stem cells in lung cancers. Although further experiments are necessary to confirm our hypothesis, it could be an important key to study the molecular mechanisms of lung carcinogenesis and clinical implications.
